CORT: Corcept Therapeutics Incorporated Stock

by  •  • Comments Off on CORT: Corcept Therapeutics Incorporated Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 5,728.84
Enterprise Value ($M) 5,601.17
Book Value ($M) 679.59
Book Value / Share 6.44
Price / Book 8.43
NCAV ($M) 310.64
NCAV / Share 2.94
Price / NCAV 18.44

Profitability (mra)
Return on Invested Capital (ROIC) 0.21
Return on Assets (ROA) 0.23
Return on Equity (ROE) 0.28

Liquidity (mrq)
Quick Ratio 3.26
Current Ratio 3.35

Balance Sheet (mrq) ($M)
Current Assets 471.60
Assets 840.55
Liabilities 160.96
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 675.04
Operating Income 136.95
Net Income 141.21
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Potentially Dilutive Securities Stock Options Outstanding n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 198.07
Cash from Investing -177.60
Cash from Financing -28.35

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-21 13G/A Ingalls & Snyder Llc 7.80 -1.07
02-14 13G/A Belanoff Joseph K 6.30 3.65
2024-02-14 13G/A Baker G Leonard Jr 5.30 0.50
2024-02-13 13G/A Vanguard Group Inc 9.25 -7.81
2024-02-13 13G/A Renaissance Technologies Llc 6.52 -7.72

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-10-30 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly peri
2024-07-29 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly peri
2024-05-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly peri

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 520,866 1,237,802 42.08
2025-03-06 368,638 1,513,245 24.36
2025-03-05 350,104 1,038,642 33.71
2025-03-04 671,761 1,670,205 40.22
2025-03-03 403,050 1,309,808 30.77

(click for more detail)

Similar Companies
CNTX – Context Therapeutics Inc. COCP – Cocrystal Pharma, Inc.
COEP – Coeptis Therapeutics Holdings, Inc. COYA – Coya Therapeutics, Inc.
CPRX – Catalyst Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Corcept Therapeutics